A U.S. Food and Drug Administration advisory panel recommended the approval of Pfizer Inc.'s Xeljanz to treat a chronic bowel disease, Reuters reported.
The panel, which consisted of 15 members, unanimously voted in a favor of the drug to treat patients with moderate to severe ulcerative colitis, an inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract.
The FDA is not required to act on the advice of its advisory panels but generally does so.
Xeljanz is already approved to treat rheumatoid arthritis and psoriatic arthritis.
